First Clinical Use of INTRABEAM in India
(Thomson Reuters ONE) - Corporate news announcement processed and transmitted by Hugin AS.The issuer is solely responsible for the content of this announcement. ------------------------------------------------------------------------------------ Carl Zeiss Meditec installs first mobile radiation system for thetreatment of breast cancer in IndiaJENA/Germany - 02 December 2009.Carl Zeiss Meditec has installed the first mobile radiationinstrument - INTRABEAM - for intraoperative breast cancer therapy atthe Indo-American Cancer Center in Hyderabad, India. With INTRABEAM,there is now a radiation system for breast cancer therapy with provenpatient benefits on the Indian market. For example, study resultsshow that the recurrence rate after five years is maybe reduced toless than half of that expected with traditional treatments.Dr. Ch. Mohana Vamsy from the Indo-American Cancer Institute andResearch Centre, Hyderabad, who advocated the purchase of INTRABEAMfor the hospital, is convinced of the method. "The boost withINTRABEAM enables radiation directly in the tumor bed during theprocedure. This is gentler on the surrounding healthy tissue, is thusbetter tolerated and also shows high clinical effectiveness. Targetedintraoperative radiation therapy (TARGIT) with INTRABEAM thereforeoffers clear treatment benefits for our patients."This treatment approach was inspired by original research in Indiaand UK by Dr. Jayant S. Vaidya, who developed it at UniversityCollege London, and gave the first treatment in 1998. This treatmentis now being used in many centres around the world. As a pioneer inTARGIT, Dr. Vaidya has come to India to demonstrate the firstoperation with INTRABEAM. "This is ideal technology for India and ithas been my dream to bring it here for the last 10 years. I amthrilled that women in India will now benefit from targetedintraoperative radiotherapy. In some patients TARGIT could reducetreatment time to just one session in the operation theatre, or inothers it could improve the control of cancer. Soon, it could savemany women from choosing a mastectomy. This marks a milestone inbreast cancer treatment and opens up entirely new opportunities forpatients and doctors in India for treatment and research of breastcancer," says Dr. Vaidya.Dr. Michael Kaschke, President and CEO of Carl Zeiss Meditec AG,explains that "the verification of the effectiveness and treatmentbenefits of INTRABEAM by doctors around the world motivates us towork even harder. Our attention is now being focused on sales andmarketing in order to spread the innovative power of this new methodon the basis of the clinical results and stimulate further growth.With the installation of the first INTRABEAM in India, we have takena giant step towards opening up this urge market."Further informationBreast cancer is the most common form of the disease in women.Today's treatment standard is the breast-conserving removal of thetumor in combination with external, 6-week radiotherapy with a tumorbed boost.In intraoperative radiotherapy the tumor bed is irradiatedisotropically with soft X-rays after resection of the breast tumor.To date, more than 3000 women have received intraoperativeradiotherapy with the INTRABEAM device all over the world.Clinical outcomes of intraoperative boost therapy of breast cancerusing the INTRABEAM show a local recurrence rate of only 1.5 percent.This is considerably lower than the expected recurrence rate ofaround 3 to 5 percent in the first five years after surgery intraditional radiotherapy. Therefore, the method not only offers thebenefit that traditional radiotherapy can be reduced by one to twoweeks because part of the radiotherapy already takes place duringsurgery, but is also anticipated to be more effective than thetraditional technique.The international clinical study "TARGIT" is currently examining thepossibility of offering IORT in the future as the sole method ofradiotherapy in selected cases of early breast cancer in addition toboost irradiation with the INTRABEAM. Initial results are alreadyexpected next year.Contact:Eva SesselmannDirector CZM Group CommunicationsCarl Zeiss Meditec AGGöschwitzer Strasse 51-5207745 JenaGermanyPhone: +49 (0) 3641/ 220-331Fax: +49 (0) 3641/ 220-112Email: press(at)meditec.zeiss.comPatrick KoflerDirector Investor RelationsCarl Zeiss Meditec AGGöschwitzer Strasse 51-5207745 JenaGermanyPhone: +49 (0) 3641/ 220-106Fax: +49 (0) 3641/ 220-117Email: investors(at)meditec.zeiss.comBrief profileCarl Zeiss Meditec AG (ISIN: DE0005313704) is one of the world'sleading medical technology companies.The Company supplies innovative technologies and application-orientedsolutions which enable doctors to improve the quality of life oftheir patients. The Company offers complete solutions, includingimplants and consumables, to diagnose and treat ophthalmic diseases.In the fields of microsurgery the Company provides innovativevisualization solutions. The medical technology portfolio of CarlZeiss Meditec is rounded off by promising future-orientedtechnologies such as intraoperative radiotherapy.The Company's around 2,100 employees generated revenues of about EUR600 million in fiscal year 2007/08 (ended Sept. 30). The headquartersof Carl Zeiss Meditec are located in Jena, Germany. In addition toother subsidiaries in Germany, the Company is represented by over 50percent of its employees at sites in the USA, Japan, Spain andFrance.35 percent of Carl Zeiss Meditec shares are in free float. Theremaining 65 percent are held by Carl Zeiss AG, one of the world'sleading groups in the optical and opto-electronic industry. The fiveindependently run business segments of Carl Zeiss AG operate in thefuture-oriented markets "Medical and Research Solutions", "IndustrialSolutions" and "Lifestyle Products". Carl Zeiss AG is headquarteredin Oberkochen, Germany. During fiscal year 2007/08 (ended Sept. 30)the company generated revenues of about EUR 2.7 billion. Carl Zeisshas around 13,000 employees in more than 30 countries, including over8,000 in Germany.For further information, please visit our website at:http://www.meditec.zeiss.com --- End of Message ---Carl Zeiss Meditec AGGoeschwitzer Strasse 51-52 Jena GermanyWKN: 531370; ISIN: DE0005313704; Index: Prime All Share, TECH All Share, TecDAX;Listed: Freiverkehr in Bayerische Börse München, Freiverkehr in Börse Stuttgart, Freiverkehr in Börse Berlin, Freiverkehr in Börse Düsseldorf, Freiverkehr in Hanseatische Wertpapierbörse zu Hamburg, Freiverkehr in Niedersächsische Börse zu Hannover, Prime Standard in Frankfurter Wertpapierbörse, Regulierter Markt in Frankfurter Wertpapierbörse;
Datum: 02.12.2009 - 14:14 Uhr
Sprache: Deutsch
News-ID 9151
Anzahl Zeichen: 0
contact information:
Town:
London
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 650 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"First Clinical Use of INTRABEAM in India"
steht unter der journalistisch-redaktionellen Verantwortung von
Carl Zeiss Meditec AG (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
